Abstract
Background COVID-19 has directly and indirectly caused high mortality worldwide.
Aim To explore patterns of mortality during the COVID-19 pandemic and implications for palliative care provision, planning, and research.
Design Descriptive analysis and population-based modelling of routine data.
Participants and setting All deaths registered in England and Wales between 7th March and 15th May 2020. We described the following mortality categories by age, gender and place of death: 1) baseline deaths (deaths that would typically occur in a given period) 2) COVID-19 deaths 3) additional deaths not directly attributed to COVID-19. We estimated the proportion of COVID-19 deaths among people who would be in their last year of life in the absence of the pandemic, using simple modelling with explicit assumptions.
Results During the first 10 weeks of the pandemic there were 101,615 baseline deaths, 41,105 COVID-19 deaths and 14,520 additional deaths. Deaths in care homes increased by 220% compared to home and hospital deaths which increased by 77% and 90%. Hospice deaths fell by 20%. Additional deaths were among older people (86% aged ≥75 years), and most occurred in care homes (56%) and at home (43%). We estimate that 44% (38% to 50%) of COVID-19 deaths occurred among people who would have been in their last year of life in the absence of the pandemic.
Conclusions Healthcare systems must ensure availability of palliative care to support people with severe COVID-19 in community and hospital settings. Integrated models of palliative care in care homes are urgently needed.
What is already known about the topic?
The COVID-19 pandemic has directly and indirectly resulted in high mortality in many affected nations.
Internationally the response has been focused on prevention and curative treatments, with little emphasis on palliative care needs of people dying during the COVID-19 pandemic.
We do not know how many of those dying with COVID-19 would have been in their last year of life in the absence of the pandemic, and this group may have distinct care needs.
What this paper adds
The number of people dying in care homes trebled during the first 10 weeks of the COVID-19 pandemic in England and Wales; many of these deaths were ‘additional deaths’, that is associated with the COVID-19 pandemic but not directly as a result of COVID-19.
We estimate almost half of all COVID-19 deaths occurred among people who would have been in their last year of life in the absence of the pandemic.
Implications for practice, theory or policy
Healthcare systems must ensure availability of palliative care to support people with severe COVID-19 in community and hospital settings.
The need for integrated models of palliative care in care home settings is imperative and research to underpin these models is warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by Dunhill Medical Trust and Cicely Saunders International. KES is funded by a National Institute of Health Research (NIHR) Clinician Scientist Fellowship (CS-2015-15-005), IJH is an NIHR Senior Investigator Emeritus. IJH is supported by the NIHR Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. IJH leads the Palliative and End of Life Care theme of the NIHR ARC South London, and co-leads the national theme. AMF is funded by Marie Curie. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care or the funding charities.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No ethical approval required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
anna.bone{at}kcl.ac.uk
anne.finucane{at}maricurie.org.uk
javiera.martelli{at}kcl.ac.uk
Irene.higginson{at}kcl.ac.uk
Katherine.sleeman{at}kcl.ac.uk
Data Availability
All data is publicly available.
